| Authors: |
Li BT; Memorial Sloan Kettering Cancer Center, New York, NY., Gandhi L; Dana-Farber Cancer Institute, Boston, MA., Ravichandran V; Memorial Sloan Kettering Cancer Center, New York, NY., Besse B; Gustave Roussy, Paris Saclay University, Villejuif, France., Mazières J; Hôpital Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France., Shapiro GI; Dana-Farber Cancer Institute, Boston, MA., Boni V; NEXT Madrid, University Hospital Quironsalud, Pozuelo de Alarcón, Madrid, Spain., Waqar SN; Washington University School of Medicine in St Louis, St. Louis, MO., Park H; Washington University School of Medicine in St Louis, St. Louis, MO., Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA., Martinez A; Instituto Oncológico Dr Rosell, Hospital Universitario Dexeus, Grupo Quiron Salud, Les Corts, Barcelona, Spain., Stemmer SM; Davidoff Center, Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel., Cortot AB; University of Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Barlesi F; University Paris Saclay, France., Quoix E; UNISTRA, Strasbourg, Strasbourg, France., Burkard ME; University of Wisconsin, Madison WI., Selcuklu SD; Memorial Sloan Kettering Cancer Center, New York, NY., Hunt C; Memorial Sloan Kettering Cancer Center, New York, NY., Donoghue MTA; Memorial Sloan Kettering Cancer Center, New York, NY., Kris MG; Memorial Sloan Kettering Cancer Center, New York, NY., Bebchuk J; Puma Biotechnology, Inc., Los Angeles, CA., Eli LD; Puma Biotechnology, Inc., Los Angeles, CA., McCulloch L; Puma Biotechnology, Inc., Los Angeles, CA., Solit DB; Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: solitd@mskcc.org., Jänne PA; Dana-Farber Cancer Institute, Boston, MA. |
